Non-small Cell Lung Cancer
Exelixis initiates Phase II trial for XL647 in patients with metastatic non-small cell lung cancer
Published in Cancer Weekly, August 29th, 2006
Although these individual RTKs are targets for currently approved therapies, XL647 was designed to potently inhibit all three targets simultaneously. The trial will be conducted in patients with advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC) who have not previously been treated with chemotherapy. In this proof-of-concept trial, participants must meet at least two of the following criteria: Asian, female, non-smoker or adenocarcinoma.
"We designed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-29)
More Articles from Cancer Weekly
- Cancer Therapy
Ambitious research program in pharmacogenetics aims to individualize cancer treatment - Colorectal Adenoma
Advanced colorectal adenoma recurrence risk reduced with high dry bean intake - Ovarian Cancer
Ovarian cancer risk potentially reduced with paracetamol use - Pancreatic Cancer
Pancreatic carcinogenesis possibly prevented by targeting nuclear factor kappa B - Acoustic Neuromas
House Clinic offers Gamma Knife technology as treatment for acoustic neuromas - Acute Myeloid Leukemia
Acute myeloid leukemia survival improved with high-dose cytosine arabinoside - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
